Pheast Therapeutics
Provider of immuno-oncology therapies intended to activate the innate immune system to fight cancer. The company offers an anti-CD24 macrophage checkpoint inhibitor engineered to induce macrophages to...
Valuation
$154.6M
Market implied
Share Price
N/A
Total Raised
$100.6M
Last Round
N/A